Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 3/20 | 0.33 |
| ▸ | CCNK | O75909 | 2/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | GRK5 | P34947 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.31 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23341625 | 0.71 | TSHR (0.36) | — | |
| SCHEMBL23324958 | 0.66 | HCAR3 (0.32) | — | |
| SCHEMBL24127270 | 0.63 | HPGD (0.35) | — | |
| SCHEMBL16063986 | 0.58 | FFAR2 (0.32) | — | |
| SCHEMBL22915324 | 0.58 | FFAR2 (0.32) | — | |
| SCHEMBL22153119 | 0.57 | — | — | |
| SCHEMBL17920146 | 0.57 | ALDH1A1 (0.33) | — | |
| SCHEMBL27151520 | 0.56 | ALDH1A1 (0.39) | — | |
| SCHEMBL20416193 | 0.54 | TGM2 (0.50) | JAK3BTKEGFR | |
| SCHEMBL20322708 | 0.53 | HCAR3 (0.51) | CCNKCDK12EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | KRAS 1/4885CCNK 304/4885CDK12 879/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885CCNK 304/4885CDK12 879/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885CCNK 304/4885CDK12 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.